Sec Form 13G Filing - RA CAPITAL MANAGEMENT L.P. filing for Travere Therapeutics Inc. (TVTX) - 2023-05-15

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934

 

(Amendment No. 4)*

 

TRAVERE THERAPEUTICS, INC.

(Name of Issuer)

 

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

 

89422G107

(CUSIP Number)

 

May 15, 2023

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

x Rule 13d-1(b)

¨ Rule 13d-1(c)

¨ Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

CUSIP No. 89422G107

 

1.	Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only).   RA Capital Management, L.P.
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a)       ¨  (b)       ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization	Delaware

 

Number of Shares	5.	Sole Voting Power	0 shares
Beneficially  Owned by	6.	Shared Voting Power	0 shares
Each Reporting Person With	7.	Sole Dispositive Power	0 shares
	8.	Shared Dispositive Power	0 shares

9.	Aggregate Amount Beneficially Owned by Each Reporting Person   0 shares
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)	¨
11.	Percent of Class Represented by Amount in Row (9) 0%
12.	Type of Reporting Person (See Instructions) IA, PN

 

 

CUSIP No. 89422G107

 

1.	Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only).   Peter Kolchinsky
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a)       ¨  (b)       ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization	United States

 

Number of Shares	5.	Sole Voting Power	0 shares
Beneficially  Owned by	6.	Shared Voting Power	0 shares
Each Reporting Person With	7.	Sole Dispositive Power	0 shares
	8.	Shared Dispositive Power	0 shares

9.	Aggregate Amount Beneficially Owned by Each Reporting Person   0 shares
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)	¨
11.	Percent of Class Represented by Amount in Row (9) 0%
12.	Type of Reporting Person (See Instructions) HC, IN

 

 

CUSIP No. 89422G107

 

1.	Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only).   Rajeev Shah
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a)       ¨  (b)       ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization	United States

 

Number of Shares	5.	Sole Voting Power	0 shares
Beneficially  Owned by	6.	Shared Voting Power	0 shares
Each Reporting Person With	7.	Sole Dispositive Power	0 shares
	8.	Shared Dispositive Power	0 shares

9.	Aggregate Amount Beneficially Owned by Each Reporting Person   0 shares
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)	¨
11.	Percent of Class Represented by Amount in Row (9) 0%
12.	Type of Reporting Person (See Instructions) HC, IN

 

 

CUSIP No. 89422G107

 

1.	Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only).   RA Capital Healthcare Fund, L.P.
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a)       ¨  (b)       ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization	United States

 

Number of Shares	5.	Sole Voting Power	0 shares
Beneficially  Owned by	6.	Shared Voting Power	0 shares
Each Reporting Person With	7.	Sole Dispositive Power	0 shares
	8.	Shared Dispositive Power	0 shares

9.	Aggregate Amount Beneficially Owned by Each Reporting Person   0 shares
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)	¨
11.	Percent of Class Represented by Amount in Row (9) 0%
12.	Type of Reporting Person (See Instructions) HC, IN

 

 

CUSIP No. 89422G107

 

Item 1.

 

(a)

Name of Issuer:

 

Travere Therapeutics, Inc. (the “Issuer”).

 

(b)

Address of the Issuer’s Principal Executive Offices:

 

3611 Valley Centre Drive, Suite 300; San Diego, CA 92130

 

Item 2.

 

(a)

Name of Person Filing:

 

The names of the persons filing this report (collectively, the “Reporting Persons”) are:

 

RA Capital Management, L.P. (“RA Capital”)

Peter Kolchinsky

Rajeev Shah

RA Capital Healthcare Fund, L.P. (the “Fund”)

 

(b)

Address of Principal Business Office:

 

The principal business office of the Reporting Persons is c/o RA Capital Management, L.P., 200 Berkeley Street, 18^th Floor, Boston, MA 02116.

 

(c)

Citizenship:

 

RA Capital and the Fund are Delaware limited partnerships. Dr. Kolchinsky and Mr. Shah are United States citizens.

 

(d)

Title and Class of Securities:

 

Common stock, par value $0.0001 (“Common Stock”)

 

(e)

CUSIP Number:

 

89422G107

 

 

CUSIP No. 89422G107

 

Item 3.

If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

(e) RA Capital Management, L.P. is a registered investment adviser and is filing this statement in accordance with §240.13d-1(b)(1)(ii)(E);

 

(g) Peter Kolchinsky and Rajeev Shah are control persons and are filing this statement in accordance with §240.13d-1(b)(1)(ii)(G).

 

Item 4.

Ownership:

 

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

 

(a)	Amount Beneficially Owned: See the response(s) to Item 9 on the attached cover page(s).
(b)	Percent of Class: See the response(s) to Item 11 on the attached cover page(s).
(c)	Number of shares as to which such person has:
	(i)	sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s).
	(ii)	shared power to vote or to direct the vote See the response(s) to Item 6 on the attached cover page(s).
	(iii)	sole power to dispose or to direct the disposition of See the response(s) to Item 7 on the attached cover page(s).
	(iv)	shared power to dispose or to direct the disposition of See the response(s) to Item 8 on the attached cover page(s).

 

Item 5.

Ownership of Five Percent or Less of a Class:

 

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.

 

Item 6.

Ownership of More than Five Percent on Behalf of Another Person:

 

Not applicable.

 

 

CUSIP No. 89422G107

 

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person:

 

Not applicable.

 

Item 8.

Identification and Classification of Members of the Group:

 

Not applicable.

 

Item 9.

Notice of Dissolution of Group:

 

Not applicable.

 

Item 10.

Certification:

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

 

 

CUSIP No. 89422G107

 

Exhibit List

 

Exhibit 1: Joint Filing Agreement

 

 

CUSIP No. 89422G107

 

SIGNATURE

 

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

 

Date:	May 15, 2023
RA CAPITAL MANAGEMENT, L.P.
By:	/s/ Peter Kolchinsky
	Name:	Peter Kolchinsky
	Title:	Authorized Signatory
PETER KOLCHINSKY
/s/ Peter Kolchinsky
RAJEEV SHAH
/s/ Rajeev Shah
RA CAPITAL HEALTHCARE FUND, L.P.
By:	RA Capital Healthcare Fund GP, LLC
Its:	General Partner
By:	/s/ Peter Kolchinsky
	Name:	Peter Kolchinsky
	Title:	Manager

 

 

CUSIP No. 89422G107

 

EXHIBIT 1

 

AGREEMENT

 

This Joint Filing Agreement, dated as of May 15, 2023, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”).

 

Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13G and/or 13D with respect to Common Stock, $0.0001 par value per share of Travere Therapeutics, Inc. beneficially owned by them from time to time.

 

Pursuant to and in accordance with Rule 13(d)(1)(k) promulgated under the Securities Exchange Act of 1934, as amended, the Filers hereby agree to file a single statement on Schedule 13G and/or 13D (and any amendments thereto) on behalf of each of such parties, and hereby further agree to file this Joint Filing Agreement as an exhibit to such statement, as required by such rule.

 

This Joint Filing Agreement may be terminated by any of the Filers upon one week’s prior written notice or such lesser period of notice as the Filers may mutually agree.

 

Executed and delivered as of the date first above written.

 

RA CAPITAL MANAGEMENT, L.P.
By:	/s/ Peter Kolchinsky
	Name:	Peter Kolchinsky
	Title:	Authorized Signatory
PETER KOLCHINSKY
/s/ Peter Kolchinsky
RAJEEV SHAH
/s/ Rajeev Shah
RA CAPITAL HEALTHCARE FUND, L.P.
By:	RA Capital Healthcare Fund GP, LLC
Its:	General Partner
By:	/s/ Peter Kolchinsky
	Name:	Peter Kolchinsky
	Title:	Manager